LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical trial.
The trial was a phase-two open-label, multi-centre trial of ezutromid, an utrophin modulator in patients with DMD. Previous 24-week interim data from the trial showed evidence of utrophin production being maintained, and significantly reduced muscle inflammation and damage after ezutromid dosing.
Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy and is caused by the lack of dystrophin, a protein that maintains healthy muscle function. Utrophin is a naturally occurring protein that be potentially substituted for dystrophin.
"We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In the full trial results, we aim to see continued utrophin modulation and sustained changes in magnetic resonance parameters. These results, if positive, could form the basis of a regulatory filing of ezutromid, bringing this universal treatment to patients more rapidly," said Chief Medical Officer David Roblin.
Shares in Summit Therapeutics were up 1.2% at 189.75 pence on Thursday.
